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Abstract.  Tenascin is an extracellular matrix  glyco- 
protein expressed in association with mesenchymal- 
epithelial interactions during development and in the 
neovasculature and stroma of undifferentiated tumors. 
This selective expression of tenascin indicates a  spe- 
cific role in cell matrix  interactions.  We now show 
that tenascin can support the adhesion of a variety of 
cell types, including various human tumor cells, nor- 
mal fibroblasts, and endothelial cells, all of which can 
attach to a  substrate coated with tenascin.  Detailed 
studies on the mechanism of the tenascin-promoted 
cell attachment were carried out with the human gli- 
oma cell line U251MG. The attachment of these cells 
and others to tenascin were inhibited specifically by 
peptides containing the RGD cell attachment  signal. 
Affinity chromatography procedures similar to those 
that have been used to isolate other adhesion receptors 
yielded a heterodimeric cell surface protein which 
bound to a tenascin affinity matrix in an RGD-depen- 
dent fashion.  One of the subunits of this putative 
tenascin receptor comigrates with the/3 subunit of the 
fibronectin receptor in SDS-PAGE and cross reacts 
with antibodies prepared against the fibronectin recep- 
tor in immunoblotting.  These results identify the 
tenascin receptor as a member of the fibronectin 
receptor family within the integrin  superfamily of 
receptors.  The cell attachment response on tenascin is 
distinctly different from that seen on fibronectin,  sug- 
gesting that cell adhesion and motility may be modu- 
lated at those sites where tenascin is expressed in the 
extracellular matrix. 
T 
hE  extracellular  matrix  is  a  complex  assembly of 
molecules that  interact  with one another as well as 
with cells to effect a wide range of cellular and tissue 
functions.  The extracellular  matrix molecules include fibro- 
nectin,  laminin,  interstitial  and basement membrane colla- 
gens, and proteoglycans.  A number of these molecules have 
been shown to have important  functional  properties includ- 
ing the promotion of cell adhesion and spreading, cell motil- 
ity, directed cell migration,  cellular differentiation,  and pro- 
liferation (Cardarelli and Pierschbacher,  1986; Couchman et 
al.,  1982; Edgar et al.,  1984; Ekblom,  1984; Gospodaro- 
wicz et al., 1980; Greenberg and Hay, 1986; Lacovara et al., 
1984; Manthorpe et al.,  1983; Rovasio et al.,  1983; Ruos- 
lahti and Pierschbacher,  1987).  More recently,  it has been 
found that  a  number  of extracellular  matrix  components 
interact  with cells through  specific  cell  surface receptors 
(Giancotti  et al.,  1985; Horwitz et al.,  1985; Pytela et al., 
1985a,b; Pytela et al.,  1986; Takada et al.,  1989; Tamkun 
et al., 1986; Tomaselli et al., 1987). These receptors belong 
to an integrin  superfamily  of proteins  and many  of them 
recognize  the tripeptide  sequence Arg-Gly-Asp  (RGD)  in 
their extracellular  ligands (Hynes, 1987; Pierschbacher and 
Ruoslahti,  1984a;  Ruoslahti  and  Pierschbacher,  1987). 
While a number of extraeellular  matrix molecules have been 
well-characterized,  new molecules are likely to be found that 
play specific roles in cell matrix interactions. 
One such novel extracellular  matrix molecule is the glial- 
mesenchymal  extracellular  matrix  glycoprotein  tenascin 
(Bourdon et al.,  1983;  Chiquet-Ehrismann  et al.,  1986). 
This glycoprotein  has been described as GMEM (Bourdon 
et al., 1983) cytotactin (Grumet et al., 1985), hexabrachion 
protein (Erickson and Taylor, 1987), and myotendinous anti- 
gen (Chiquet  and Fambrough,  1984). Human tenascin  is a 
250-kD glycoprotein  that  is secreted as a  high  molecular 
mass (>10  ~ kD) disulfide-bonded  oligomer (Bourdon et al., 
1983; Bourdon et al.,  1985).  In rotary shadowing  images 
tenascin appears as a hexameric structure (Erickson and Tay- 
lor,  1987; Vaughn et al.,  1987).  This structurally  unusual 
matrix molecule is further distinguished  by its highly selec- 
tive oncodevelopmental  expression. 
Tenascin is expressed in a variety of solid tumors,  but is 
largely absent in normal adult tissues (Bourdon et al., 1983; 
Mackie et  al.,  1987; McComb et al.,  1987).  In  human 
gliomas,  it is expressed around the tumor neovasculature, 
and in fibrosarcornas  within  the stroma.  Developmentally, 
tenascin is selectively expressed in condensing mesenchyme 
during the initial stages of  organogenesis of  mammary gland, 
toothbud, and kidney  (Aufderheide  et al.,  1987; Chiquet- 
Ehrismann  et al.,  1986).  In each of these organs,  epithe- 
lial-mesenchymal interactions  are of key importance in nor- 
mal organ development.  Temporally restricted expression of 
tenascin is also seen in the developing nervous system (Gru- 
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codevelopmental expression of tenascin within the extracel- 
lular matrix makes it likely that this molecule plays a specific 
role in cell-matrix interactions and that such interactions are 
mediated by cell surface receptors. 
In this study, we show that tenascin has RGD-dependent 
cell adhesion activity and describe an integrin-type cell sur- 
face receptor that binds to tenascin with the same RGD- 
dependent specificity as the cells. 
Materials and Methods 
Cell Culture 
Tumor  cell  lines  and  normal  fibroblasts  were  cultured  in  DME  sup- 
plemented with 10%  FBS, glutamine, penicillin, and streptomycin. Cul- 
tures were maintained at  37°C  in 7%  CO2.  Human  umbilical vein en- 
dotheliai  cells were  cultured  in  DME,  supplemented with  20%  FBS, 
heparin, and endothelial cell growth factors (Collaborative Research, Lex- 
ington, MA).  Adherent cell lines were passaged by treatment with  100 
/tg/ml trypsird0.02 % EDTA in PBS. 
Cell Attachment Assay 
Cells for the cell attachment assay were detached using 0.02 % EDTA in 
PBS, pH 7.4,  washed in DME containing 2 mg/ml BSA and plated at 2  x 
104 cells per well in 96-well flat bottom microtitrntion plates (Titertek; 
Flow Laboratories, McLean, VA). Wells were previously coated overnight 
with dilutions of cell attachment proteins in PBS. Plates were washed and 
then incubated for 30 min with a  solution containing the DMEM-BSA 
medium to block nonspecific  binding sites before their use in cell attachment 
assays. Peptides added to the cell attachment assays were dissolved in DME. 
The peptides were not cytotoxic at the concentration used as determined by 
trypan blue exclusion by cells in the assays. Assays were carried out at 3"/°C 
in a C(h incubator for 90 min. Nonadherent cells were removed by wash- 
ing with PBS  and adherent cells fixed with 3%  paraformaidehyde and 
stained  with  0.5%  toluidine  blue.  Adherent cells  were  either  counted 
directly or their numbers determined by lysing cells with 1% SDS and mea- 
suring dye absorbance at 600 run in a Multiscan plate reader (Flow Labora- 
tories). 
Purification of Tenascin 
Tenascin was purified from the spent culture media of U251MG human 
glioma cells by affinity chromatography on an 81C6 antitenascin monoclonal 
antibody (Bourdon et ai., 1983) coupled to Sepharose 4B. The spent culture 
media was first concentrated by tangential flow filtration over PLMK300 
filters (Millipore Corp., Bedford, MA). A Sepharose 4B column was used 
to remove debris and aggregated protein before application of the sample 
to  the  monoclonal antibody  affinity  column.  Nonbound  proteins  were 
washed from the antibody-Sepharose column with 0.5 M NaCI,  1 M urea, 
10 mM sodium phosphate, pH 7.4,  and tenascin eluted with 0.5 M NaC1, 
4 M urea, 10 mM sodium phosphate, pH 7.4. Protein elution was monitored 
at 280 urn. Purity of  the tenascin preparations was monitored by SDS-PAGE 
analysis on 7 % acrylamide gels followed by Coomassie Blue or silver stain- 
ing, by HPLC chromatography on a TSK-400 column (7.5  x  60 nun), and 
by ELISA. Fibronectin and vitronectin were purified from human plasma 
as described (Hayman et al.,  1983;  Engvall and Ruoslahti, 1977).  Rotary 
shadowing of purified tenascin was performed using standard procedures 
(Engvall  et al.,  1986),  and the shadowed molecules were imaged on a 
Hitachi H-60 scanning-transmission electron microscope. 
Isolation of Cell Surface Receptors 
The receptor isolation was carried out essentially as described (Pytela et ai., 
1985a,b). Pools of 10  s cells were surface labeled with IzsI and lysed in 50 
mM octylglucoside, 1 mm CaCI2,  1 mM MgCIe, 0.15 NaCI, 1 mm PMSF, 
10 mM Tris, pH 7.2.  Cell extracts were passed over tenascin-Sepharose, 
GRGDSPK-Sepharose, or  fibronectin 120-kD  fragment-Sepharose col- 
umns, the affinity columns were washed with 25 mM octylthioglucoside, 
1 mM CaCl2, 1 mM MgCI2 alone, or with 1 mg/ml GRGESP peptide, and 
the receptors were eluted with 1 mg/ml GRGDSP peptide. Fractions were 
analyzed by SDS-PAGE and autoradiography on XAR5 x-ray film with an 
enhancer screen. 
Immunoblot and Immunoprecipitation Analyses 
Receptors isolated as described above from unlabeled cells were concen- 
trated by precipitation in acetone and separated by SDS-PAGE on 7.5% 
acrylamide gel.  The separated proteins were then electroblotted onto a 
nitrocellulose membrane. Blotted protein bands were visualized by staining 
the membrane with ponceau S stain and destained in PBS. The blots were 
incubated in PBS containing 1% BSA for 1-2 h to block nonspecific pro- 
tein binding sites and subsequently incubated with primary antibodies in 
PBS-I% BSA overnight at 4°C. After the incubation, the blots were washed 
and incubated with either HRP-conjugated goat anti-mouse IgG or goat 
anti-rabbit  IgG  antibodies  (Bio-Rad  Laboratories,  Richmond,  CA)  in 
PBS-I% BSA for 1 h. Bound antibodies were visualized by addition ofdi- 
aminobeuzidine tetrahydrochloride in PBS 0.01% H202 solution to washed 
blots. 
Immunoprecipitation was performed by incubating 125I-labeled samples 
with antireceptor antisera overnight at 4°C,  followed by recovery of the 
bound label with protein A-Sepharose. Bound material was analyzed by 
SDS-PAGE followed by fluorography as described above. 
Antibodies 
Monoclonal antibody 81C6 is an antitenascin antibody previously described 
(Bourdon et al., 1983).  Polyclonal antisera against tenascin were prepared 
by immunization of rabbits with purified human tenascin. The antisera were 
absorbed with fibronectin-Sepharose and bovine plasma protein-Sepha- 
rose, and their IgG fraction was isolated on protein A-Sepharose. 
Polyclonai rabbit antibodies to vitronectin receptor were affinity purified 
on vitronectin receptor-Sepharose (Suzuki et al.,  1987).  Polyclonal rabbit 
antibodies to fibronectin receptor/~ subunit were affinity purified as de- 
scribed (Argraves et al.,  1987). 
Synthetic Peptides 
The peptide GRGDSP derived from the fibronectin cell attachment site and 
control peptide GRGESP were synthesized on a peptide synthesizer (Ap- 
plied Biosystems Inc., Foster City, CA) using solid phase chemistry. Pep- 
tides were purified by ion exchange HPLC and lyophilized. Peptides were 
resuspended in appropriate buffered solutions for cell attachment assays or 
elution of tenascin receptors. 
Results 
Isolation and Characterization of Tenascin 
Human tenascin was isolated from spent culture media of 
U251MG human glioma cells by 81C6 monoclonal antibody 
affinity chromatography. The purified tenascin migrated as 
a  single prominent band at '~250 kD in SDS-PAGE under 
reducing conditions (Fig. 1 A). Unreduced tenascin behaved 
as  a  high  molecular  mass  (>106 kD)  disulfide  bonded 
oligomer both in SDS-PAGE  and HPLC TSK 400  sizing 
chromatography (not shown). In electron microscopic im- 
ages obtained after rotary shadowing, tenascin appeared as 
a hexameric oligomer (Fig.  1 B).  Polyclonal antiserum to 
chicken tenascin (Chiquet and Fambrough, 1984) immuno- 
precipitated the  same  250-kD  tenascin polypeptide from 
U251MG  spent culture medium as the 81C6 antibody (not 
shown). These results identify the isolated protein as highly 
purified tenascin. 
Cell Attachment Activity of Tenascin 
Cell attachment to tenascin was examined in an in vitro cell 
attachment assay. Cells adhering to tenascin included a vari- 
ety of tumor cell lines of glial (U251MG,  Rugli),  epithelial 
(A431),  endodermal (PFHR-9),  and mesencbymal (MG63, 
HT1080) origin as well as fibroblasts, and human umbilical 
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electron microscopy. (A) Tenascin (20 ~g) isolated from the spent 
culture  media  of U251MG cells  by affinity chromatography  on 
monoclonal antibody 81C6-Sepharose was characterized by SDS- 
PAGE on a 7 % acrylamide gel under reducing conditions. Protein 
was stained with Coomassie Blue. (B) A rotary shadowed image 
of one tenascin molecule  is shown. 
vein  endothelial  cells.  Human  M21  melanoma  cells,  F9 
mouse embryonic carcinoma cells and cells of lymphoid ori- 
gin (El_A, WR.1, thymocytes), and monocytic U937 cells ad- 
hered poorly or not at all to tenascin. Results for the attach- 
ment of U251MG cells to tenascin are shown in Figs. 2 and 3. 
The morphology of cells adhering  to  tenascin  was dis- 
tinctly different from the morphology of cells adhering to 
fibronectin or vitronectin.  The U251MG cells generally as- 
sumed a more polar, elongated morphology on tenascin with 
larger  numbers  of cellular  extensions  and  less  extensive 
spreading than they did on fibronectin (Fig. 2) or on vitro- 
nectin  (not  shown).  Cells  remained  attached  to  tenascin- 
coated wells for periods of up to at least 24 h. Cells cultured 
for 24 h on fibronectin or vitronectin appeared indistinguish- 
able from cells adhering to tenascin. Despite the reduced cell 
spreading observed for cells adhering to tenascin, the level 
of cell attachment to tenascin was found to be similar to the 
level of attachment to fibronectin. As shown for the U251MG 
cells in Fig. 3, the cell attachment titration curves for tenas- 
cin and fibronectin closely paralleled one another with maxi- 
mum  cell  attachment  (75-85%  of cells  added)  on  either 
tenascin or fibronectin occurring at a coating concentration 
of 3 tzg/ml protein and higher.  The similarity of the attach- 
ment efficiencies of  the two proteins indicated that the attach- 
ment of cells to tenascin  was not due to contamination of 
tenascin by fibronectin.  This was further supported by the 
finding that there was no detectable fibronectin in tenascin 
samples as tested by ELISA. Moreover, antitenascin antibod- 
ies blocked cell attachment to tenascin but not to fibronectin 
(Fig. 4), whereas antifibronectin antibodies inhibited cell at- 
tachment to fibronectin, but not to tenascin. Neither type of 
antibody inhibited the attachment of cells to vitronectin. 
Figure 2.  Cell attachment to purified tenascin.  The attachment of 
U251MG cells to tenascin (TN), fibronectin (FN), and bovine se- 
rum albumin (BSA) are shown. Microtiter wells were coated with 
5 #g/rnl protein in PBS. Cells were seeded into the coated wells at 
a density of 2  x  104 cells/200/zl  in DME-BSA and incubated at 
37°C for 90 rain.  Bar, 100/zm. 
Inhibition of Cell Attachment to Tenascin by 
RGD Peptides 
The peptide GRGDSP inhibited  the cell attachment of the 
U251MG cells to tenascin in a dose-dependent manner (Fig. 
5),  while the control peptide GRGESP (Pierschbacher and 
Ruoslahti,  1984b) had no effect, even at high concentrations 
(10 mg/ml, not shown). 
Inhibition of cell attachment to tenascin by the GRGDSP 
peptide occurred at concentrations of 30 and 150 times lower 
than were needed for comparable inhibition of cell attach- 
ment on vitronectin or fibronectin (Fig. 5).  The concentra- 
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Figure 3.  Comparison  of cell attachment activity of tenascin and 
fibronectin.  The attachment of U251MG cells to microtiter  wells 
coated with tenascin (0) or fibronectin (t~) at various concentra- 
tions  was assayed.  Cells  at 2  x  104/200 ~1 in DME-BSA were 
seeded into the wells and allowed to adhere.  The cell attachment 
activity  is plotted  relative to maximum cell attachment  to fibro- 
nectin. 
tion of GRGDSP resulting in a 50 % inhibition of cell attach- 
ment to tenascin was 25 #g/ml, whereas 500/~g/ml and 4.5 
mg/ml, respectively, were necessary to produce the same de- 
gree of inhibition on vitronectin and fibronectin. 
RGD-dependent Tenascin Receptor 
A  receptor for tenascin  was  isolated  from octylglucoside 
extracts  of surface-labeled cells  by  affinity  chromatogra- 
phy on a tenascin-Scpharose column. After the column was 
washed with octylthioglucoside, it was eluted with peptides, 
first GRGESP and then GRGDSP. As has been found to be 
the case with other RGD-directed receptors (Pytela et al., 
1985a,b), the GRGESP peptide at 1 mg/ml eluted from the 
tenascin column a small proportion of protein, but the bulk 
Figure 4. Inhibition of tenascin-mediated  cell attachment by anti- 
tenascin antibodies.  Cell attachment to fibronectin (FN), tenascin 
(TN), and vitronectin (VN) was assayed in the presence or absence 
of polyclonal antifibronectin antibodies and polyclonal antitenascin 
antibodies.  Wells were coated with 5 #g/ml of adhesion protein. 
Antibody concentrations per well were 20/zg/ml antifibronectin an- 
tibody or 200/~g/ml antitenascin antibody. Values represent relative 
cell attachment  +  SD.  Controls  represent  maximum cell attach- 
ment on each adhesion protein in the absence of added antibody. 
u, control;  [], anti-TN;  [], anti-FN. 
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Figure 5. Effect of GRGDSP peptide on tenascin-mediated cell at- 
tachment.  Cell  attachment  to tenascin  ([]),  vitronectin  (.),  and 
fibronectin  (u),  in  the  presence  of  various  concentrations  of 
GRGDSP peptide is shown. Wells were coated with 3 ttg/ml adhe- 
sion protein and 2  x  104 cells added in serum-free media contain- 
ing increasing amounts of GRGDSP peptide. 
of the bound protein eluted with the GRGDSP peptide. SDS- 
PAGE revealed specifically eluted 145- and 125-kD polypep- 
tides (Fig. 6 A). The eluted material also contained a minor 
band at •200  kD, the identity of which was not studied fur- 
ther because it was not observed in all receptor preparations. 
Upon reduction of disulfide bonds, the GRGDSP-eluted mate- 
rial gave only a one major band at 130 kD, presumably because 
the main polypeptides comigrate after reduction (Fig. 6 B). 
The decrease of the size of the larger (ct) subunit on reduc- 
tion indicated the ot subunit may be composed of a heavy and 
light chain as is seen for the fibronectin receptor a  subunit. 
However, the light chain of the tenascin receptor ct subunit 
could not be readily identified in the reduced receptor prepa- 
rations, perhaps due to a paucity of radiolabeling sites in this 
particular chain. The polypeptide composition is similar to 
that of the integrin-type adhesion receptors (Hynes,  1987; 
Ruoslahti and Pierschbacher,  1987). In particular the tenas- 
cin receptor/3 subunit had the same chain mobility as the 
fibronectin receptor/~ subunit,  suggesting that the tenascin 
receptor was a member of the fibronectin receptor subfamily 
of integrins. This assumption was confirmed by immunologi- 
cal analysis as shown below. 
The tenascin receptor was compared with the vitronectin 
receptor  and  fibronectin  receptor  isolated  from  U251MG 
cell extracts. The previously characterized vitronectin recep- 
tor (Pytela et al.,  1985b)  was obtained when the U251MG 
cell extract was fractionated on a GRGDSP-Sepharose affin- 
ity matrix (not shown).  The tenascin receptor did not bind 
detectably to a  GRGDSPK-Sepharose column.  Moreover, 
the  tenascin  receptor could be isolated on tenascin-Seph- 
arose even after the U251MG extract was first passed over 
GRGDSPK-Sepharose.  Similar experiments with the cell- 
binding  120-kD  fragment  of  fibronectin  (Pytela  et  al., 
1985a)  showed that the U251MG cells also have a  distinct 
fibronectin receptor (Fig. 7) and that no detectable tenascin 
receptor bound to this affinity matrix. 
Receptor immunoprecipitation and immunoblotting were 
used to confirm the heterodimer composition of the receptor 
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was isolated on tenascin-Sepharose from 125I cell surface labeled 
U251MG cells, solubilized in 50 mM octylglucoside, 1 mM CaCl2, 
1 mM MgC12. (A) Tenascin receptor was eluted from a 1-ml tenas- 
cin-Sepharose  column with  1 mg/ml GRGDSP peptide in octyl- 
thioglucoside, 1 mM CaC12, 1 mM MgC12 (lanes 2-5). The column 
was first washed with 1 mg/ml GRGESP peptide in octylthiogluco- 
side as above (lane 1, final wash fraction). Fraction volumes were 
0.5 ml. Samples of each fraction were subjected to electrophoresis 
on a 7 % SDS-acrylamide gel under reducing conditions and au- 
toradiographed. (B) Comparison of t25I-labeled tenascin receptor 
subjectedto electrophoresis on a 7.5 % SDS-acrylamide gel under 
reducing  (1)  and  nonreducing  (2)  conditions.  Molecular  mass 
markers in kilodaltons are shown. 
and to identify the/3 subunit of the tenascin receptor. The 
tenascin receptor ot and/3 subunits were both immunopre- 
cipitated with antifibronectin receptor/3 subunit polyclonal 
antibodies, suggesting an immunologic identity between the 
subunits of  these receptors (Fig. 7, left). Receptor immuno- 
blots with an antifibronectin receptor/3 subunit monoclonal 
antibody confirmed the immunological similarity between 
the  tenascin  receptor and  fibronectin receptor /3  subunits 
(Fig. 7). Based on these results it appears that the two recep- 
tors share the same/3 subunit. The ot subunit of the tenascin 
receptor was not reactive with an antibody against the fibro- 
nectin receptor o~ subunit and neither subunit of the tenascin 
receptor bound anti-vitronectin receptor antibodies. 
Discussion 
In this paper we have shown by using cell attachment assays 
that tenascin can interact with cells in an RGD-dependent 
manner and have isolated and.partially characterized a recep- 
tor that binds to tenascin with a  similar specificity as the 
cells. 
Cell attachment assays showed that human tenascin insol- 
ubilized on plastic  interacts with a  number of tumor and 
normal cell types supporting their attachment.  Perhaps as 
significant was the finding that at least several cell lines and 
lymphoid cells did not attach or attached poorly to tenascin. 
This may indicate that these cells either lack cell receptors 
or  the  receptor  interaction  is  not  detectable  by  cell  at- 
tachment. 
Titration  curves  comparing  the  attachment  of cells  to 
tenascin and fibronectin in a serum-free medium showed that 
similar numbers of cells attached to the two proteins. Inhibi- 
tion of cell attachment to tenascin by tenascin-specific anti- 
bodies  but  not  by  antifibronectin  antibodies,  indicated  a 
specific interaction of tenascin with the cells. Among the cell 
lines tested, the U251MG glioma cells attached to tenascin 
particularly well, and these cells were chosen for detailed 
studies on the cell-tenascin interaction. 
Tenascin appears to be a member of  the RGD family of  cell 
attachment proteins (Ruoslahti and Pierschbacher, 1987), as 
demonstrated by the specific, dose-dependent inhibition of 
cell attachment to tenascin by RGD peptides. These results 
imply the presence of an RGD sequence within the tenascin 
polypeptide and, indeed at least chicken cytotactin (tenascin) 
does contain this sequence (Jones et al.,  1988). 
Previous work on the cellular interactions of tenascin has 
indicated that tenascin lacks cell attachment-promoting ac- 
tivity (Erickson and Taylor, 1987) or that it can interact with 
cells promoting attachment, but is an inhibitor of fibronec- 
tin-mediated  cell  attachment  (Chiquet-Ehrismann  et  al., 
1988), These results are not necessarily in conflict with ours 
for the following reasons. 
Our results show that the cell attachment-promoting activ- 
ity  to  tenascin  is  distinct  from  that  of  fibronectin  and 
vitronectin in that little cell spreading is seen on tenascin. 
The cell attachment-inhibiting activity observed by others 
could be  an  indication  that  the  cell-tenascin  interaction, 
which initially manifests itself as cell attachment, is primar- 
ily a signal for another type of response, such as migration 
or differentiation. In this  regard,  the cell attachment-pro- 
moting activity of tenascin might be considered a manifesta- 
tion of an interaction between the cell and tenascin rather 
than an indication of the physiological result of the interac- 
tion. in fact, it is an exciting possibility that while some ex- 
tracellular matrix molecules give to cells signals leading to 
attachment and  spreading  others may signal migration or 
even detachment.  In addition to tenascin,  such a  role has 
been proposed for thrombospondin (Lahav,  1988),  which 
may also interact with cells in an RGD-dependent manner 
(Lawler and Hynes,  1986). 
We find that the cell-tenascin interaction can be inhibited 
with an RGD peptide, and others have found that soluble 
tenascin inhibits the attachment of cells to an RGD peptide 
substrate (Chiquet-Ehrismann et al.,  1988). However, these 
investigators also found that the soluble RGD peptide was not 
capable of inhibiting  the  attachment of the  same  cells to 
tenascin. The reasons for this difference are not known, but 
it may be that cells can also bind to tenascin through a non- 
RGD-dependent mechanism.  Fibronectin and laminin are 
each known to have more than one integrin-type receptor 
(Gehlsen et al.,  1988; Hemler et al.,  1987;  Horwitz et al., 
1985; Ignatius and Reichardt, 1988; Johansson et al.,  1987; 
Pytela et al.,  1985a,  1986; Takada et al.,  1988; Wiersma et 
al., 1988), and other types of molecules, such as proteogly- 
cans, can also mediate cell attachment to fibronectin (LeBa- 
ron et al., 1988; Saunders and Bernfield, 1988). If  more than 
one receptor exists for tenascin, differences in the source of 
tenascin, the methods used in its isolation, the cell type em- 
ployed in the assays and the details of the assay methodology 
may favor one receptor over others, explaining the divergent 
observations by different laboratories. From our results it ap- 
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blotting analysis of tenascin, fibronectin and vi- 
tronectin receptors.  Immunoprecipitation (far 
left): Affinity-purified tenascin receptor (TNR) 
was immunoprecipitated  with polyclonal anti- 
bodies to the fibronectin receptor B subunit and 
analyzed by SDS-PAGE on a 7.5 % acrylamide 
gel  under  nonreducing conditions.  Immuno- 
blots: Affinity-purified tenascin receptor (TNR), 
fibronectin  receptor (FNR), and a vitronectin 
receptor  (VNR)  all  from the  U251MG  cells 
were subjected to electrophoresis  as above and 
electroblotted  onto nitrocellulose  membranes 
for immunoblotting.  The antibodies  used were 
an antifibronectin  receptor fl subunit monoclo- 
hal  antibody 442  (Anti-FNR~;  Cheresh,  D., 
J. O.  Gailit,  and  E.  Ruoslahti,  unpublished 
results),  a rabbit antibody prepared  against the 
cytoplasmic peptide of the fibronectin  receptor 
~x subunit  (Anti-FNRc~; Argraves,  W. S.,  and 
E. Ruoslahti,  unpublished  results),  and poly- 
clonal antivitronectin  receptor antibodies  (An- 
ti-VNR). Approximately  equal amounts  of re- 
ceptor  protein  were  blotted  as  estimated  by 
Ponceau-S  staining  before  immunoblotting. 
Relative positions of a and/~ subunits are indi- 
cated. 
pears  that one mechanism whereby cells can interact with 
tenascin is through an RGD-dependent integrin-type receptor. 
The tenascin receptor we have isolated has a/$ subunit that 
is similar and possibly identical to the fibronectin receptor 
/3 subunit.  This fl subunit is shared by at least six different 
integrins that together comprise the fibronectin receptor or 
VLA family within the integrin superfamily (Hynes,  1987; 
Ruoslahti  and  Pierschbacher,  1987;  Hemler  et  al.,  1987; 
Takada et al.,  1988).  Like the other integrins,  the tenascin 
receptor appears to be a heterodimer of the B subunit and an 
ot subunit, because the two subunits coprecipitated upon im- 
munoprecipitation with antibodies reactive with the/3  sub- 
unit. The ot subunit of the tenascin receptor is clearly distinct 
from the fibronectin receptor ot subunit, but whether it might 
be identical to one of the many other known integrin o~ sub- 
units will have to be determined in future studies. It will also 
be important to determine whether tenascin is the only ligand 
for the receptor we have identified.  The affinity chromatog- 
raphy results presented here suggest that it does not bind to 
fibronectin and that it has a specificity different from that of 
the vitronectin receptor. However, the lack of sufficient quan- 
tifies  of the  receptor  has  so  far  precluded  more  detailed 
specificity studies by assays such as the liposome assay used 
with other receptors (Pytela et al.,  1985a,b). 
A  functional difference between tenascin and fibronectin 
or vitronectin is suggested by the differences in cell morphol- 
ogy seen as cells attach to these proteins.  Since tenascin is 
selectively  expressed  in  developing  organs  and  in  tumors 
(Aufderheide et al.,  1987; Bourdon et al.,  1983;  Chiquet- 
Ehrismann et al., 1986; Grumet et al., 1985), the interaction 
of cells with tenascin may have a special significance in cell 
differentiation,  proliferation, and migration. Our identifica- 
tion of the first receptor for tenascin will facilitate studies on 
the involvement of tenascin in these phenomena. The semi- 
tivity of  this receptor to inhibition by RGD peptides indicates 
that these peptides can be used to probe its functional role 
without  substantially  affecting the  functions  of other  inte- 
grins. 
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